RxDoctor Payments Data

Bao Bui, MD

Cardiovascular Disease · Fountain Valley, CANPI 1801099593

Payments from drug & device makers

$430,431in general payments, 2019–2025

Across 849 payments — averaging $506.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$113K
  • Merck$107K
  • Johnson & Johnson$66K
  • Boehringer Ingelheim$55K
  • Lilly USA, LLC$50K
  • AstraZeneca$29K
  • plus $9K from 30 others

What the payments were for

  • Consulting fees$1,6410%
  • Speaking & faculty fees$366,05485%
  • Travel & lodging$42,03410%
  • Food & beverage$20,5155%
  • Education$1870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$430,431 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$857,426
Medicare patients
814
Services billed
11,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban298$314,028
JardianceEmpagliflozin285$308,482
EntrestoSacubitril/Valsartan192$219,545
OzempicSemaglutide149$184,116
FarxigaDapagliflozin Propanediol184$178,040
KerendiaFinerenone113$129,471
BrilintaTicagrelor126$113,758
VerquvoVericiguat58$55,912
EliquisApixaban43$48,298
Repatha SureclickEvolocumab79$45,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$44,758
RybelsusSemaglutide23$44,565
VascepaIcosapent Ethyl77$35,887
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$34,377
CreonLipase/Protease/Amylase21$29,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$29,365$326,174355 claims
Boehringer IngelheimJardiance, Tradjenta$55,357$317,751301 claims
Johnson & JohnsonXarelto$66,152$314,028298 claims
Novo NordiskOzempic, Rybelsus$112,953$228,681172 claims
NovartisEntresto$1,422$219,545192 claims
BayerKerendia$1,919$129,471113 claims
MerckVerquvo, Januvia, Janumet$107,173$82,36484 claims
PfizerEliquis$294$48,29843 claims
Lilly USA, LLCTrulicity$50,021$23,12720 claims
Lexicon Pharmaceuticals, Inc.Inpefa$187$14,14325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →